In H1 and iPSC-2 human pluripotent stem cells, 100 nM BC2059 for 24 hours decreased OCT4, NANOG, REX1 and hTERT transcripts relative to DMSO. The authors used Adooq BC2059 (A14381); the study does not validate a current product lot. [4]
AML TBL1–β-catenin complex disruption and proteasome control
Cell-based study · HL-60 and OCI-AML3 cells; primary FLT3-ITD and FLT3 wild-type AML cells [1]
BC2059 reduced co-immunoprecipitated TBL1–β-catenin in cultured and primary AML cells. In cultured cells, carfilzomib restored β-catenin protein, supporting proteasome involvement; this is cellular complex evidence, not a purified-protein binding affinity.
Literature-Reported Treatment Conditions
- Treatment concentration
- Cultured cells: 100 nM BC2059; primary FLT3-ITD: 100 nM; primary FLT3-WT: 50, 100, 200 nM (Figure 2A,B). Proteasome control: 100 nM BC2059 ± 10 nM carfilzomib (Figure 2D).
- Exposure duration
- 8 h
- Method
- Co-immunoprecipitation/immunoblot; whole-cell immunoblot with β-actin loading control
- Vehicle
- Untreated (0 nM) comparator; vehicle identity not specified for these panels
- Co-treatment
- Carfilzomib only for the proteasome-control experiment; single-agent BC2059 complex-disruption panels kept distinct
- Reported limits
- Exact n for the Figure 2 blots is not stated in the caption. No quantitative dissociation constant is established by this design.
Methods and source locations
Compound reported in the paper: BC2059 (tegavivint); Compound label in the paper: BC2059
Evidence for the named research compound under the reported conditions; no salt conversion or validation of a current Adooq lot.
Figure 2A,B,D and caption; Results: Treatment with BC2059 disrupts the binding of β-catenin and TBL1; Reagents and antibodies; Immunoprecipitation
TBL1-associated β-catenin, with reciprocal IP in cultured cells: Co-IP and immunoblot — Figure 2A,B; caption
β-catenin protein with carfilzomib control: Immunoblot; carfilzomib-alone and combination controls; β-actin loading control — Figure 2D; corresponding Results
Stemness and hTERT marker response in human pluripotent stem cells
Cell-based study · H1 human embryonic stem cells and iPSC-2 for qPCR; hPSCs for the representative immunoblot [4]
BC2059 decreased OCT4, NANOG, REX1 and hTERT transcripts in the displayed H1 and iPSC-2 comparisons. The representative immunoblot showed decreased β-catenin and phosphorylated mTOR/p70S6K.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 nM
- Exposure duration
- 24 h
- Method
- qPCR and western blotting
- Vehicle
- DMSO comparator shown in Figure 5E–G
- Reported limits
- The caption does not identify the hPSC line in panel G. Do not assign the PNU-74654 proliferation experiments in Figure 5A–D to BC2059.
Methods and source locations
Compound reported in the paper: BC2059 (tegavivint); Compound label in the paper: BC2059
Evidence for the named research compound under the reported conditions; no salt conversion or validation of a current Adooq lot.
Figure 5E–G and caption; Results: β-catenin influence on hPSC fate with the correlation of mTOR; Antibodies and reagents; Cell culture; Western blotting
OCT4, NANOG, REX1 and hTERT mRNA relative to DMSO: qPCR; Figure 5 caption reports means ± SD after GAPDH normalization — Figure 5E,F; caption; associated Results
β-catenin, phospho-mTOR and phospho-p70S6K protein: Western blot; total mTOR, total p70S6K and β-actin displayed — Figure 5G; corresponding Results
DLBCL protein-complex response and β-catenin dependence controls
Cell-based study · Riva, OCI-Ly3, Pfeiffer and WSU-NHL DLBCL cells; Riva and Pfeiffer for co-IP/ChIP [2]
Tegavivint disrupted the TBL1/β-catenin association and reduced β-catenin promoter recruitment, yet MYC transcript did not fall. β-catenin knockdown had minimal effects on cell viability or MYC/SURVIVIN protein, limiting a purely β-catenin-dependent explanation in these models.
Literature-Reported Treatment Conditions
- Treatment concentration
- Riva and Pfeiffer: 70 nM; OCI-Ly3: 50 nM; WSU-NHL: 15 nM (Figure 4 caption, all drug experiments)
- Exposure duration
- 12 h for co-IP/PLA, ChIP and qRT-PCR; 24 h for drug-treatment immunoblots. Genetic-control viability: 72 h post-transduction.
- Method
- Co-IP/PLA, ChIP, immunoblot and qRT-PCR; β-catenin knockdown as mechanistic control
- Vehicle
- DMSO (NT) drug control; genetic control for knockdown
- Reported limits
- These cellular experiments do not measure direct binding affinity. No drug dose is assigned to the genetic-only controls.
Methods and source locations
Compound reported in the paper: BC2059 (tegavivint); Compound label in the paper: tegavivint
Evidence for the named research compound under the reported conditions; no salt conversion or validation of a current Adooq lot.
Figure 4A–F and caption; Results: TBL1 modulates Wnt targets in a novel, post-transcriptional, β-CATENIN independent manner; shared Methods; Supplementary Appendix pp1,4–5
TBL1–β-catenin association and MYC/BIRC5 promoter occupancy: Co-IP includes IgG; ChIP includes preimmune control; n=3, means ± SEM for ChIP — Figure 4A,B; caption
MYC protein and MYC mRNA: Immunoblot with GAPDH loading control; qRT-PCR, n=3, means ± SEM — Figure 4C,E; caption; associated Results
MYC/SURVIVIN protein and cell viability after β-catenin knockdown: Two β-catenin-targeting shRNAs; control comparator; trypan-blue viability, n=3, means ± SEM — Figure 4F and caption
Wnt reporter and cell-death comparison in engineered HEK 293 cells
Cell-based study · HEK 293 TCF/LEF luciferase reporter cells (BPS Bioscience 60501) [3]
Tegavivint did not consistently suppress Wnt-stimulated reporter output under the tested conditions, whereas IWR-1-endo did. Tegavivint caused cell death in a separate 24-hour comparison, unlike IWR-1-endo.
Literature-Reported Treatment Conditions
- Treatment concentration
- Reporter panel: tegavivint 1 μM; IWR-1-endo 1 μM. Death panel: tegavivint 1.25 μM; IWR-1-endo 1 μM.
- Exposure duration
- 4 h compound exposure for reporter panel (figure label); 24 h for separate cell-death panel
- Method
- Luminescence normalized to DMSO/Wnt3a; cell death measured by SYTOX Green-positive object counts
- Vehicle
- DMSO; reporter background from DMSO without Wnt3a
- Co-treatment
- Wnt3a stimulation in the reporter assay; IWR-1-endo and CIL56 are separate comparator arms, not combination drugs
- Reported limits
- Methods also describe sublethal 100 nM tegavivint experiments; those are not assigned to the displayed 1 μM panel. These results do not prove the absence of TBL1 binding.
Methods and source locations
Compound reported in the paper: BC2059 (tegavivint); Compound label in the paper: tegavivint
Evidence for the named research compound under the reported conditions; no salt conversion or validation of a current Adooq lot.
Figure 5f,g and caption; Results: Tegavivint does not inhibit the Wnt/β-catenin pathway; Methods: Chemicals, Cell lines and culture conditions, β-catenin reporter assays
Wnt3a-stimulated TCF/LEF reporter luminescence: One-way ANOVA with Tukey posthoc tests; individual datapoints from three or more independent experiments; no precise effect magnitude inferred — Figure 5f and caption; β-catenin reporter assay methods
SYTOX Green-positive dead-cell objects: Dead-cell imaging; individual datapoints from three or more independent experiments — Figure 5g and caption